Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An announcement from Abivax SA ( (FR:ABVX) ) is now available.
Abivax SA has reached a critical milestone in its phase 3 ABTECT clinical trial, with over 1,000 patients recruited to study the efficacy of obefazimod for ulcerative colitis. This achievement positions the company to complete recruitment by Q2 2025 and potentially submit a new drug application in the United States by H2 2026, assuming positive results. With a strong cash position supporting its operations through Q4 2025, Abivax is well-placed to continue its strategic focus on addressing unmet medical needs in the treatment of chronic inflammatory diseases.
More about Abivax SA
Abivax SA is a clinical-stage biotechnology company based in France and the United States, focusing on developing therapeutic treatments that harness the body’s natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases. Its lead drug candidate, obefazimod (ABX464), is in phase 3 clinical development for treating moderately to severely active ulcerative colitis.
YTD Price Performance: -0.15%
Average Trading Volume: 806
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €427.5M
Learn more about ABVX stock on TipRanks’ Stock Analysis page.
